Sinaptica Therapeutics
Manufacturing · Massachusetts, United States · 1-10 Employees
View Company Info for Free
Overview
Headquarters
245 1st St Ste 18, Cambridge, Massachuse...Website
www.sinapticatx.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
1
1
1
1
1
1
About Sinaptica Therapeutics
Sinaptica Therapeutics is a clinical-stage neuromodulation therapeutics company leading the development of a new class of personalized therapeutics to revolutionize the treatment of Alzheimer's and neurodegenerative diseases. The company's SinaptiStim System utilizes a novel, noninvasive approach to treating AD via neurostimulation of key networks in the brain, enhancing neuroplasticity and slowing disease progression by 80% on all four gold-standard cognitive and functional clinical endpoints in a placebo-controlled clinical study, with results published in the peer-reviewed journal Brain. The SinaptiStim System was granted Breakthrough Device Designation by the FDA in 2022 and the company is preparing for a pivotal randomized controlled clinical trial in 2024. Sinaptica's mission is to bring a safe, effective, and noninvasive neuromodulation therapy to Alzheimer's patients that can help to significantly slow the progression of both cognitive and functional decline.Explore more
Sinaptica Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Sinaptica Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Sinaptica Therapeutics is spiking on competitors!
Sinaptica Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Check if Sinaptica Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Sinaptica Therapeutics launches new products
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Sinaptica Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Sinaptica Therapeutics has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Sinaptica Therapeutics had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at Sinaptica Therapeutics
Recommended Actions
Reach out to Masked Content who joined Sinaptica Therapeutics as Masked Content
Find more new buyers
Compare Similar Companies to Sinaptica Therapeutics
Compare insights from companies similar to Sinaptica Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Sinaptica Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Sinaptica Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Sinaptica Therapeutics.
Sinaptica Therapeutics Tech Stack
A closer look at the technologies used by Sinaptica Therapeutics
Sinaptica Therapeutics News & Media
Sinaptica Therapeutics Completes Scientific Advisory Board, Bringing Together Leading Voices Across Patients, Science, Medicine, and Commercial Strategy
CAMBRIDGE, Mass., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Sinaptica Therapeutics, a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Alzheimer’s and other primary neurodegenerative diseases, today announced the completion of its Scientific Advisory Board (SAB), bringing together a uniquely comprehensive group of experts spanning neuroscience, clinical development, brain health, patient advocacy and commercial strategy.Enrollment Initiated for Phase 2 Clinical trial in Early Alzheimer’s with Sinaptica’s Second-Generation Precision Neuromodulation System
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Alzheimer’s and other primary neurodegenerative diseases, today announced that its second-generation dual stimulation technology is now being tested in a newly launched phase 2 study. The trial has enrolled its first patients and will enroll up to 60 with early-stage Alzheimer’s into this randomized, double-blind sSinaptica Announces Initiation of Co-Development of the SinaptiStim® Precision Neuromodulation System to treat Alzheimer’s Disease; On Track for Pivotal Clinical Trial Initiation in 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Alzheimer’s and other primary neurodegenerative diseases, today announced that co-development of the SinaptiStim® Neuromodulation System is underway, with planned March delivery of the first clinical system for validation testing and use in forthcoming clinical trials. Partner Nexstim (NXTMH:HEX) is customizing thePersonalized Neuromodulation Treatment Significantly Slowed Alzheimer’s Progression in 12-month Phase 2 Study, Meeting Primary and Key Secondary Endpoints
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized neuromodulation therapeutics to treat Alzheimer’s and other primary neurodegenerative diseases, today announced results of a 52-week Phase 2 study in Mild-to -Moderate Alzheimer’s disease patients showing that non-invasive personalized neuromodulation of the Default Mode Network (DMN), a key network in the brain involved in memory, “nDMN”, met all key
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Sinaptica Therapeutics
Sign Up For FreeTo access detailed company insights
Sinaptica Therapeutics is a clinical-stage neuromodulation therapeutics company leading the development of a new class of personalized therapeutics to revolutionize the treatment of Alzheimer's and neurodegenerative diseases. The company's SinaptiStim System utilizes a novel, noninvasive approach to treating AD via neurostimulation of key networks... Read More
